By webmin on
Phone
N/A
Email
N/A
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=sanofi&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d
Acknowledgement
1 business day
EA Page
http://en.sanofi.com/Innovation/clinical-trials-and-results/compassionate-use-e…
Sponsor
Genzyme, a Sanofi Company
Sanofi
COVID-19 Information

First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19

  • Phase 2/3 trial initiated in Italy, Spain, Germany, France, Canada and Russia and is enrolling patients immediately
  • Kevzara inhibits IL-6, which may play a role in driving the inflammatory immune response that causes acute respiratory distress syndrome observed in patients with severe COVID-19 infection
  • Sanofi is leading trials outside the U.S., while Regeneron is leading U.S. trials

For more info, go to:  Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

See also: https://clinicaltrials.gov/ct2/results?cond=COVID+OR+SARS+OR+MERS+OR+CORONAVIRUS&term=sarilumab&strd_s=01%2F01%2F2020&strd_e=&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=c&recrs=d&recrs=f&recrs=k

See also Regeneron in the company directory

Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19

Stage
Phase 3
Phase 2
Pre-clinical
Company Type
Vaccine
Late Onset Intervention
Expanded Access Listings

Alglucosidase Alfa Temporary Access Program

Conditions
Glycogen Storage Disease Type II (GSD-II)
Pompe Disease (Late-Onset)
Acid Maltase Deficiency Disease
Glycogenosis 2

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiencyof a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA isused by the body's cells to break down glycogen (a stored form of sugar) withinspecialized structures called lysosomes. In patients with Pompe disease, an excessiveamount of glycogen accumulates and is stored in various tissues, especially heart andskeletal muscle, which prevents their normal function. The objective of this expandedaccess study is to provide patients with Pompe disease in the United States (US), accessto alglucosidase alfa produced from a scaled up manufacturing process for a limited timeuntil production at this scale is approved for commercial use by the Food and DrugAdministration.